|
Balance Sheet Cash Flow Statement Piazza XX Settembre, 2 22079 Villa Guardia, Como, Italy Tel. +39-031-385-217 Fax +39-031-385-241 |
Type: Public
On the web:
http://www.gentium.it
Employees:
74
Employee growth: (7.5%)
Gentium wants to soften the harsh effects of cancer treatment. The company seeks to minimize the damage done by cancer treatments such as chemotherapy and radiation therapy. The company's most advanced product candidates use defibrotide to relieve blood vessel disorders caused by such treatments, and could also have applications in additional inflammation and vascular disorders. Gentium also manufactures and sells active pharmaceutical ingredients, including heparin, an anticoagulant.
Key numbers for fiscal year ending December, 2008:
Sales: $10.5M
One year growth: (6.4%)
Net income: ($28.1)M
Officers:
Interim CEO and Director: Khalid Islam
EVP and CFO: Biopharmaceuticals & Biotherapeutics
Competitors:
AtheroGenics
Bristol-Myers Squibb
Genzyme
